News and Trends 11 Sep 2024 Can Europe revive its biopharma innovation leadership? Find out if the biotech runner-up, Europe, can step up to boost research and revive its innovation leadership. September 11, 2024 - 9 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
News and Trends 6 Sep 2024 Psychedelic therapies under scrutiny: What’s next after Lykos’ MDMA rejection? Delve into the psychedelic-assisted therapy market and investors’ sentiment after the FDA’s decision about Lykos’ therapy. September 6, 2024 - 8 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
News and Trends 2 Sep 2024 Are we in an AI bubble? Biotech AI startups’ value plummet and leads to restructuration Delve into the downturn AI is experiencing in biotech: Is the bubble bursting or is the market correcting the high expectations? September 2, 2024 - 13 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
Podcast 30 Aug 2024The future of combination vaccines To look at combination vaccines, listen to our conversation with Cesar Sanz Rodriguez, vice president, Europe & Switzerland, medical affairs, at Moderna. August 30, 2024 Share WhatsApp Twitter Linkedin Email Listen Now Apple Music Spotify More
News and Trends 27 Aug 2024 Could microbiome drugs be the key to unlocking checkpoint inhibitors’ potential? As Microbiotica announces phase 1 approval for two microbiome drugs we delve into their potential in oncology and beyond. August 27, 2024 - 11 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
Podcast 23 Aug 2024New German biotech spins out to develop radiotherapeutics While it is currently owned by the Eckert & Ziegler Group, Pentixapharm will soon be spun off as a separate company. Listen to our conversation with Andreas Eckert, founder of the company August 23, 2024 Share WhatsApp Twitter Linkedin Email Listen Now Apple Music Spotify More
Best in Biotech 22 Aug 2024 Seven companies transforming the biotech industry in Italy Delve into Italy’s biotech landscape with seven companies that are leading the charge in the European country. August 22, 2024 - 9 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
In Depth 1 Aug 2024 CureVac: From a failed drug to a €1.45 billion deal In 2021, CureVac’s COVID-19 candidate came short. Discover how the company leveraged its deal with GSK to restructure and turn things around. August 1, 2024 - 8 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
News and Trends 29 Jul 2024 Influenza solution deals pile up as pandemic preparedness increases Influenza deals have been piling up in the last few weeks. Discover why that is and how are companies and government preparing for pandemics. July 29, 2024 - 6 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
More News! 26 Jul 2024 Confo Therapeutics raises $60 million to focus on agonistic GPCR antibodies Discover the field of agonistic GPCR antibodies after Confo therapeutics successfully raised $60 million in its series B round. July 26, 2024 - 8 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
More News! 23 Jul 2024 First AKT-targeting drug capivasertib to hit the market, could it open the door for more? As AstraZeneca and Astex’s capivasertib gains market presence in breast cancer, could it be the time for AKT inhibitors? Let’s find out! July 23, 2024 - 7 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
More News! 17 Jul 2024 Is tau protein the key to defeating Alzheimer’s? Asceneuron thinks so and raises $100 million to prove it Discover yet another exciting deal in biotech with Asceneuron raising $100 million to advance its Alzheimer’s candidate, ASN51. July 17, 2024 - 10 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email